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  We measured the serurn and urinary TPA in 64 patients with urological cancer， 55 patients
with benign urological disease and 37 hea1thy volunteers． The serum TPA levels in patients
with ’垂窒?|treated cancer were significantly higher than those of hea｝thy volunteers， but showed
no significant diff＋erence compared to those．in．patients with a benign urological disease． The
urinary TPA levels in patients with pre－treated cancer ’were significantly higher than those
with a benign urological diseasg， but in some patients with urinary tract infection， very high
urinary TPA concentrations were observed． Therefore， the determination of serum and
urinary TPA may be useful in detectinbff urological cancer， but they were not specific tests．
  On the other hand， as lower serum and ur；nary TPA levels were observed after treat－
ment of bladder and prostatic cancer， their determinations were considered to be useful in
following up patients with these cancers．
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Fig． 1． Radioimmunoassay of tissue
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Fig． 2． Serum TPA in patients with urological diseases．
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Fig． 4． Relationship between serum and
    urinary TPA in patients with
    bladder cancer．
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Fig． 5． TPA levels in patients with prostatic
    cancer before and after treatment．
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Table 1．Comparison between serum CEA
and urinary cytology
  治療前  治療後     治療lj 治 ’
Fig． 6． TPA levels in patients with bladder．
    cancer before and after treatment．
    （A） serum TPA， （B） urinary TPA．
血清TPA  GEA（Z一ゲル） 尿細胞診
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